1 ANNEX, Regulation (EU) 2018/1480

In forcesince 4 Oct 2018

Annex VI to Regulation (EC) No 1272/2008 is amended as follows:

(1)

in Part 1, the heading of point 1.1.1.4 is replaced by the following:

‘Chemical name’;

(2)

in Part 3, Table 3.1 is amended as follows:

(a)

the title of the second column is replaced by the following: ‘Chemical name’;

(b)

the title of the penultimate column is replaced by the following: ‘Specific Conc. Limits, M-factors and ATEs (*)

(*) ATEs for oral and dermal exposure routes are expressed in mg/kg bw, which stands for milligram per kilogram bodyweight.’;

(c)

the entry corresponding to index number 607-414-00-6 is deleted;

(d)

the entries corresponding to index numbers 006-044-00-7, 015-101-00-5, 016-096-00-2, 017-011-00-1, 025-002-00-9, 603-180-00-4, 604-014-00-3, 604-016-00-4, 604-090-00-8, 605-003-00-6, 606-047-009, 607-096-00-9, 607-103-00-5, 607-113-00-X, 607-373-00-4, 613-167-00-5, 613-205-00-0 and 614-001-00-4 are replaced by the following entries respectively:

Index No | Chemical name | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-factors and ATEs | Notes

Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s)

‘006-044-00-7 |

isoproturon (ISO);

3-(4-isopropylphenyl)-1,1-dimethylurea

251-835-4 | 34123-59-6 |

Carc. 2

STOT RE 2

Aquatic Acute 1

Aquatic Chronic 1

H351

H373 (blood)

H400

H410

GHS08

GHS09

Wng

H351

H373 (blood)

H410

M = 10

M = 10’

‘015-101-00-5 |

phosmet (ISO);

S-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl] O,O-dimethyl phosphorodithioate;

O,O-dimethyl-S-phthalimidomethyl phosphorodithioate

211-987-4 | 732-11-6 |

Repr. 2

Acute Tox. 4

Acute Tox. 3

STOT SE 1

Aquatic Acute 1

Aquatic Chronic 1

H361f

H332

H301

H370 (nervous system)

H400

H410

GHS08

GHS06

GHS09

Dgr

H361f

H332

H301

H370 (nervous system)

H410

M = 100

M = 100’

‘016-096-00-2 |

thifensulfuron-methyl (ISO);

methyl 3-(4-methoxy-6-methyl-1,3,5-triazin-2-ylcarbamoylsulfamoyl)thiophene-2-carboxylate

–

| 79277-27-3 |

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410 | |

M = 100

M = 100’

‘017-011-00-1 | sodium hypochlorite, solution … % Cl active | 231-668-3 | 7681-52-9 |

Skin Corr. 1B

Eye Dam. 1

Aquatic Acute 1

Aquatic Chronic 1

H314

H318

H400

H410

GHS05

GHS09

Dgr

H314

H410

EUH031 |

M = 10

M = 1

EUH031:

C ≥ 5 %

B’

‘025-002-00-9 | potassium permanganate | 231-760-3 | 7722-64-7 |

Ox. Sol. 2

Repr. 2

Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1

H272

H361d

H302

H400

H410

GHS03

GHS08

GHS07

GHS09

Dgr

H272

H361d

H302

H410’

‘603-180-00-4 |

colecalciferol;

cholecalciferol;

vitamin D3

200-673-2 | 67-97-0 |

Acute Tox. 2 Acute Tox. 2 Acute Tox. 2

STOT RE 1

H330

H310

H300

H372

GHS06

GHS08

Dgr

H330

H310

H300

H372

inhalation:

ATE = 0,05 mg/L (dusts or mists)

dermal:

ATE = 50 mg/kg bw

oral:

ATE = 35 mg/kg bw

STOT RE 1; H372: C ≥ 3 %

STOT RE 2; H373: 0,3 % ≤ C < 3 %’

‘604-014-00-3 |

chlorocresol;

4-chloro-m-cresol;

4-chloro-3-methylphenol

200-431-6 | 59-50-7 |

Acute Tox. 4

Skin Corr. 1C

Eye Dam. 1

STOT SE 3

Skin Sens. 1B Aquatic Acute 1

Aquatic Chronic 3

H302

H314

H318

H335

H317

H400

H412

GHS07

GHS05

GHS09

Dgr

H302

H314

H335

H317

H410

M = 1’ |

‘604-016-00-4 |

1,2-dihydroxybenzene;

pyrocatechol

204-427-5 | 120-80-9 |

Carc. 1Β

Muta. 2

Acute Tox. 3

Acute Tox. 3

Skin Irrit. 2

Eye Irrit. 2

H350

H341

H311

H301

H315

H319

GHS08

GHS06

Dgr

H350

H341

H311

H301

H315

H319

oral:

ATE = 300 mg/kg bw

dermal:

ATE = 600 mg/kg bw’

‘604-090-00-8 | 4-tert-butylphenol | 202-679-0 | 98-54-4 |

Repr. 2

Skin Irrit. 2

Eye Dam. 1

Aquatic Chronic 1

H361f

H315

H318

H410

GHS08

GHS05

GHS09

Dgr

H361f

H315

H318

H410

M = 1’ |

‘605-003-00-6 |

acetaldehyde;

ethanal

200-836-8 | 75-07-0 |

Flam. Liq. 1

Carc. 1B

Muta. 2

STOT SE 3

Eye Irrit. 2

H224

H350

H341

H335

H319

GHS02

GHS08

GHS07

Dgr

H224

H350

H341

H335

H319’

‘606-047-00-9 | 2-benzyl-2-dimethylamino-4′-morpholinobutyrophenone | 404-360-3 | 119313-12-1 |

Repr. 1B

Aquatic Acute 1

Aquatic Chronic 1

H360D

H400

H410

GHS08

GHS09

Dgr

H360D

H410’

‘607-096-00-9 | maleic anhydride | 203-571-6 | 108-31-6 |

Acute Tox. 4

STOT RE 1

Skin Corr. 1B

Eye Dam. 1

Resp. Sens. 1

Skin Sens. 1A

H302

H372 (respiratory system) (inhalation)

H314

H318

H334

H317

GHS07

GHS08

GHS05

Dgr

H302

H372 (respiratory system) (inhalation)

H314

H334

H317

EUH071 | Skin Sens. 1A; H317: C ≥ 0,001 %’ |

‘607-103-00-5 | succinic anhydride | 203-570-0 | 108-30-5 |

Acute Tox. 4

Skin Corr. 1

Eye Dam. 1

Resp. Sens. 1

Skin Sens. 1

H302

H314

H318

H334

H317

GHS07

GHS05

GHS08

Dgr

H302

H314

H334

H317

EUH071’ | |

‘607-113-00-X | isobutyl methacrylate | 202-613-0 | 97-86-9 |

Flam. Liq. 3

STOT SE 3

Skin Irrit. 2

Skin Sens. 1B

H226

H335

H315

H317

GHS02

GHS07

Wng

H226

H335

H315

H317

D’

‘607-373-00-4 | quizalofop-P-tefuryl (ISO); (+/–) tetrahydrofurfuryl (R)-2-[4-(6-chloroquinoxalin-2-yloxy)phenyloxy]propionate | 414-200-4 | 200509-41-7 |

Carc. 2

Repr. 2

Acute Tox. 4

STOT RE 2

Aquatic Acute 1

Aquatic Chronic 1

H351

H361fd

H302

H373

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H361fd

H302

H373

H410

M = 1

M = 1’

‘613-167-00-5 | reaction mass of 5-chloro-2-methyl-2H-isothiazol-3-one and 2-methyl-2H-isothiazol-3-one (3:1) | — | 55965-84-9 |

Acute Tox. 2

Acute Tox. 2

Acute Tox. 3

Skin Corr. 1C

Eye Dam. 1

Skin Sens. 1A Aquatic Acute 1

Aquatic Chronic 1

H330

H310

H301

H314

H318

H317

H400

H410

GHS06

GHS05

GHS09

Dgr

H330

H310

H301

H314

H317

H410

EUH071 |

Skin Corr. 1C; H314: C ≥ 0,6 %

Skin Irrit. 2; H315: 0,06 % ≤ C < 0,6 %

Eye Dam. 1; H318: C ≥ 0,6 %

Eye Irrit. 2; H319: 0,06 % ≤ C < 0,6 %

Skin Sens. 1A; H317: C ≥ 0,0015 %

M = 100

M = 100

B’

‘613-205-00-0 | propiconazole (ISO); (2RS,4RS;2RS,4SR)-1-{[2-(2,4-dichlorophenyl)-4-propyl-1,3-dioxolan-2-yl]methyl}-1H-1,2,4-triazole | 262-104-4 | 60207-90-1 |

Repr. 1B

Acute Tox. 4

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H360D

H302

H317

H400

H410

GHS08

GHS07

GHS09

Dgr

H360D

H302

H317

H410

M = 1

M = 1’

‘614-001-00-4 |

nicotine (ISO);

3-[(2S)-1-methylpyrrolidin-2-yl]pyridine

200-193-3 | 54-11-5 |

Acute Tox. 2

Acute Tox. 2

Acute Tox. 2

Aquatic Chronic 2

H330

H310

H300

H411

GHS06

GHS09

Dgr

H330

H310

H300

H411

inhalation:

ATE = 0,19 mg/L (dusts or mists)

dermal:

ATE = 70 mg/kg bw

oral:

ATE = 5 mg/kg bw’

(e)

the following entries are inserted in the appropriate places, following the order of the entries set out in Table 3.1:

Index No | Chemical name | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-factors and ATEs | Notes

Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s)

‘604-094-00-X |

isoeugenol; [1]

(E)-2-methoxy-4-(prop-1-enyl)phenol; [2]

(Z)-2-methoxy-4-(prop-1-enyl)phenol [3]

202-590-7 [1]

227-678-2 [2]

227-633-7 [3]

97-54-1 [1]

5932-68-3 [2]

5912-86-7 [3]

Skin Sens. 1A | H317 |

GHS07

Wng

H317 | | Skin Sens. 1A; H317: C ≥ 0,01 %’ |

‘607-724-00-1 | 2,3,5,6-tetrafluoro-4-(methoxymethyl)benzyl (1R,3R)-2,2-dimethyl-3-[(1Z)-prop-1-en-1-yl]cyclopropanecarboxylate; epsilon-metofluthrin | — | 240494-71-7 |

Acute Tox. 4

Acute Tox. 3

STOT SE 1

STOT RE 2

Aquatic Acute 1

Aquatic Chronic 1

H332

H301

H370 (nervous system)

H373

H400

H410

GHS06

GHS08

GHS09

Dgr

H332

H301

H370 (nervous system)

H373

H410

M = 100

M = 100’

‘607-725-00-7 | isopropyl (2E,4E,7S)-11-methoxy-3,7,11-trimethyldodeca-2,4-dienoate; S-methoprene | — | 65733-16-6 |

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410 | |

M = 1

M = 1’

‘607-726-00-2 |

pinoxaden (ISO);

8-(2,6-diethyl-4-methylphenyl)-7-oxo-1,2,4,5-tetrahydro-7H-pyrazolo[1,2-d][1,4,5]oxadiazepin-9-yl 2,2-dimethylpropanoate

–

| 243973-20-8 |

Repr. 2

Acute Tox. 4

Acute Tox. 4

Eye Irrit. 2

STOT SE 3

Skin Sens. 1A

Aquatic Acute 1

Aquatic Chronic 3

H361d

H332

H302

H319

H335

H317

H400

H412

GHS08

GHS07

GHS09

Wng

H361d

H332

H302

H319

H335

H317

H410

inhalation:

ATE = 4,63 mg/L (dusts or mists)

oral:

ATE = 500 mg/kg bw

M = 1’

‘607-727-00-8 |

tetramethrin (ISO);

(1,3-dioxo-1,3,4,5,6,7-hexahydro-2H-isoindol-2-yl)methyl 2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyclopropanecarboxylate

231-711-6 | 7696-12-0 |

Carc. 2

Acute Tox. 4

STOT SE 2

Aquatic Acute 1

Aquatic Chronic 1

H351

H302

H371 (nervous system) (inhalation)

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H302

H371 (nervous system) (inhalation)

H410

M = 100

M = 100’

‘607-728-00-3 | (1,3,4,5,6,7-hexahydro-1,3-dioxo-2H-isoindol-2-yl)methyl (1R-trans)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropanecarboxylate | 214-619-0 | 1166-46-7 |

Carc. 2

Acute Tox. 4

STOT SE 2

Aquatic Acute 1

Aquatic Chronic 1

H351

H302

H371 (nervous system) (inhalation)

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H302

H371 (nervous system) (inhalation)

H410

M = 100

M = 100’

‘607-729-00-9 |

mesosulfuron-methyl (ISO);

methyl 2-[(4,6-dimethoxypyrimidin-2-ylcarbamoyl)sulfamoyl]-α-(methanesulfonamido)-p-toluate;

–

| 208465-21-8 |

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410 | |

M = 100

M = 100’

‘607-730-00-4 |

spirodiclofen (ISO);

3-(2,4-dichlorophenyl)-2-oxo-1-oxaspiro[4.5]dec-3-en-4-yl 2,2-dimethylbutyrate

–

| 148477-71-8 |

Carc. 1B

Repr. 2

STOT RE 2

Skin Sens. 1B

Aquatic Chronic 1

H350

H361f

H373

H317

H410

GHS08

GHS07

GHS09

Dgr

H350

H361f

H373

H317

H410

M = 10’ |

‘607-731-00-X | sodium methyl [(4-aminophenyl)sulphonyl]carbamate; sodium methyl (EZ)-sulfanilylcarbonimidate; asulam-sodium | 218-953-8 | 2302-17-2 |

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H317

H400

H410

GHS07

GHS09

Wng

H317

H410

M = 1

M = 1’

‘607-732-00-5 | salicylic acid | 200-712-3 | 69-72-7 |

Repr. 2

Acute Tox. 4

Eye Dam. 1

H361d

H302

H318

GHS08

GHS07

GHS05

Dgr

H361d

H302

H318’

‘608-068-00-9 |

flutianil (ISO);

(2Z)-{[2-fluoro-5-(trifluoromethyl)phenyl]thio}[3-(2-methoxyphenyl)-1,3-thiazolidin-2-ylidene]acetonitrile

–

| 958647-10-4 | Aquatic Chronic 1 | H410 |

GHS09

Wng

H410 | | M = 100’ |

‘612-293-00-8 | reaction mass of 1-[2-(2-aminobutoxy)ethoxy]but-2-ylamine and 1-({[2-(2-aminobutoxy)ethoxy]methyl}propoxy)but-2-ylamine | 447-920-2 | - |

Repr. 2

Acute Tox. 4

Skin Corr. 1B

Eye Dam. 1

H361f

H302

H314

H318

GHS08

GHS07

GHS05

Dgr

H361f

H302

H314

EUH071’ | |

‘613-326-00-9 | 2-methylisothiazol-3(2H)-one | 220-239-6 | 2682-20-4 |

Acute Tox. 2

Acute Tox. 3

Acute Tox. 3

Skin Corr. 1B

Eye Dam. 1

Skin Sens. 1A

Aquatic Acute 1

Aquatic Chronic 1

H330

H311

H301

H314

H318

H317

H400

H410

GHS05

GHS06

GHS09

Dgr

H330

H311

H301

H314

H317

H410

EUH071 |

Skin Sens. 1A; H317: C ≥ 0,0015 %

M = 10

M = 1’

‘613-327-00-4 |

pyroxsulam (ISO);

N-(5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-2-methoxy-4-(trifluoromethyl)pyridine-3-sulfonamide

–

| 422556-08-9 |

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H317

H400

H410

GHS07

GHS09

Wng

H317

H410

M = 100

M = 100’

‘613-328-00-X | 1-vinylimidazole | 214-012-0 | 1072-63-5 | Repr. 1B | H360D |

GHS08

Dgr

H360D | | Repr. 1B; H360D: C ≥ 0,03 %’ |

‘616-224-00-2 |

amisulbrom (ISO);

3-(3-bromo-6-fluoro-2-methylindol-1-ylsulfonyl)-N,N-dimethyl-1H-1,2,4-triazole-1-sulfonamide

–

| 348635-87-0 |

Carc. 2

Eye Irrit. 2

Aquatic Acute 1

Aquatic Chronic 1

H351

H319

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H319

H410

M = 10

M = 10’